椎体骨质疏松性压缩骨折后抗骨质疏松药物降低继发骨折率而骨水泥强化未增加继发骨折率
基于PearlDiver数据库2015至2019年36145例椎体骨质疏松性压缩骨折患者,比较骨水泥强化与非手术治疗后继发骨折率,并评估抗骨质疏松药物的作用。多因素分析显示骨水泥强化未显著改变继发骨折率,抗骨质疏松药物显著降低后续压缩骨折风险19%。仅7.8%患者接受了抗骨质疏松药物处方。
要点
- 骨水泥强化(椎体成形术或后凸成形术)后继发骨折率与非手术治疗相比无显著差异。
- 接受抗骨质疏松药物治疗者继发骨折率为10.1%,未接受者为21.9%,多因素分析有显著差异。
- 仅7.8%的椎体骨质疏松性压缩骨折患者接受了抗骨质疏松药物处方。
核心结论
- 骨水泥强化未改变继发骨折率,而抗骨质疏松药物使后续骨质疏松性压缩骨折风险显著降低19%。
- 仅7.8%的患者在初始骨质疏松性压缩骨折后接受了抗骨质疏松药物处方。
研究设计与样本
- 查询PearlDiver数据库2015至2019年所有诊断为骨质疏松性压缩骨折的患者。
- 排除年龄<50岁、诊断为脊柱肿瘤或感染、或围手术期行腰椎融合术的患者。
- 采用单因素和多因素logistic回归分析评估继发骨折风险,变量包括椎体后凸成形术、椎体成形术、抗骨质疏松药物、年龄、性别和Elixhauser合并症指数。
主要发现
- 共36145例患者诊断为骨质疏松性压缩骨折,其中25904例(71.7%)接受非手术治疗,10241例(28.3%)接受骨水泥强化,包括1556例椎体成形术和8833例椎体后凸成形术。
- 非手术治疗组继发骨折率为21.8%,椎体成形术组为14.5%,椎体后凸成形术组为18.5%,多因素分析无显著差异。
- 全队列中2833例(7.8%)接受抗骨质疏松药物,33312例(92.2%)未接受;用药组继发骨折率为10.1%,未用药组为21.9%,多因素分析有显著差异(比值比=1.23,p<0.001)。
关键数值与推荐
- 骨水泥强化与非手术治疗相比继发骨折率无显著差异。
- 抗骨质疏松药物使后续骨质疏松性压缩骨折风险显著降低19%(比值比=1.23,p<0.001)。
- 证据等级:治疗性III级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Painful vertebral osteoporotic compression fractures (OCFs) are often treated with cement augmentation, although controversies exist as to whether or not this increases the secondary fracture risk. Prevention of secondary fracture includes treatment of underlying osteoporosis. The purposes of this study were to determine (1) whether cement augmentation increases the rate of secondary fracture compared with nonoperative management, (2) whether anti-osteoporotic medications reduce the rate of secondary fracture, and (3) the rate of osteoporosis treatment with medications following vertebral OCF. METHODS: The PearlDiver database was queried for all patients with a diagnosis of OCF from 2015 to 2019. Patients were excluded if they were <50 years old, had a diagnosis of spinal neoplasm or infection, or underwent lumbar fusion in the perioperative period. Secondary fracture risk was assessed using univariate and multivariate logistic regression analysis, with kyphoplasty, vertebroplasty, anti-osteoporotic medications, age, gender, and Elixhauser Comorbidity Index as variables. RESULTS: A total of 36,145 patients were diagnosed with an OCF during the study period. Of those, 25,904 (71.7%) underwent nonoperative management and 10,241 (28.3%) underwent cement augmentation, including 1,556 who underwent vertebroplasty and 8,833 who underwent kyphoplasty. Patients who underwent nonoperative management had a secondary fracture rate of 21.8% following the initial OCF, compared with 14.5% in the vertebroplasty cohort and 18.5% in the kyphoplasty cohort, which was not a significant difference on multivariate analysis. In the entire cohort, 2,833 (7.8%) received anti-osteoporotic medications and 33,312 (92.2%) did not. The rate of secondary fracture was 10.1% in patients who received medications and 21.9% in those who did not, which was a significant difference on multivariate analysis (odds ratio = 1.23, p < 0.001). CONCLUSIONS: Cement augmentation did not alter the rate of secondary fracture, whereas anti-osteoporotic medications significantly decreased the risk of subsequent OCF by 19%. Only 7.8% of patients received a prescription for an anti-osteoporotic medication following the initial OCF. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Mills ES, Hah RJ, Fresquez Z, et al. Secondary Fracture Rate After Vertebral Osteoporotic Compression Fracture Is Decreased by Anti-Osteoporotic Medication but Not Increased by Cement Augmentation. J Bone Joint Surg Am. 2022. PMID: 36223482. doi:10.2106/JBJS.22.00469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。